China Resources Sanjiu shareholders approve governance changes, routine transactions

China Resources Sanjiu Medical & Pharmaceutical held its Seventh Extraordinary General Meeting of Shareholders in 2025 on December 26, 2025, with 869 shareholders representing 66.2219% of total voting shares in attendance. Key resolutions included the approval of the 2026 annual related-party transaction forecast, the revision of the company charter, the independent director work system, the related-party transaction management measures, and the cash management system. All proposals passed with significant shareholder support, including the special resolution to amend the company charter, which received over two-thirds of the valid votes.

The 2026 related-party transaction forecast was approved with 49,058,061 votes in favor, representing 98.2442% of the total effective voting shares. Additionally, the company announced a change in its board of directors, with Mr. Cui Xingpin resigning as a director due to work adjustments. Mr. Huang Xianfeng was elected as a worker director, taking office upon the approval of the revised company charter.

These approvals formalize critical updates to the company's operational framework and board composition, ensuring compliance and strategic alignment for the coming year. The revised documents, including the company charter and the shareholder meeting rules, become effective upon shareholder approval.